Investor updates Suchbegriff Suchen Löschen 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 Published on: 22 Oktober 2020 Roche announces collaboration with Atea Pharmaceuticals to develop a potential oral treatment for COVID-19 patients mehr Published on: 19 Oktober 2020 Roche announces full FDA approval for Venclexta combinations for acute myeloid leukaemia mehr Published on: 15 Oktober 2020 Chugai Files NDA for Risdiplam as the First Oral Drug for Spinal Muscular Atrophy in Japan mehr Published on: 15 Oktober 2020 First nine months of the year with 1% sales growth at constant exchange rates, significant impact of COVID-19 pandemic mehr Published on: 13 Oktober 2020 Roche to launch laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients mehr Published on: 8 Oktober 2020 Reminder: Invitation to Roche’s 3rd Quarter Sales 2020 Webinar mehr Published on: 30 September 2020 Regeneron's REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19 Patients mehr Published on: 28 September 2020 Sarepta Therapeutics Reports Sustained Functional Improvement Two Years After Treatment with SRP-9001, its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy mehr Published on: 28 September 2020 Roche presents new 2-year data for Evrysdi (risdiplam) in infants with Type 1 spinal muscular atrophy (SMA) mehr Published on: 25 September 2020 Tecentriq in combination with Avastin in 1L HCC approved in Japan mehr Published on: 19 September 2020 Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020 mehr Published on: 18 September 2020 Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer mehr Published on: 18 September 2020 Roche launches new quantitative antibody test to measure SARS-CoV-2 antibodies, to support the evaluation of vaccines mehr Published on: 18 September 2020 Roche’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia mehr Published on: 17 September 2020 Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020 mehr Published on: 16 September 2020 Invitation to Roche’s 3rd Quarter Sales 2020 Webinar mehr Published on: 16 September 2020 Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer mehr Published on: 11 September 2020 New data further reinforce Roche’s OCREVUS (ocrelizumab) as a highly effective treatment for people with multiple sclerosis mehr Published on: 10 September 2020 New data show Roche’s ENSPRYNG (satralizumab) significantly reduces severity and risk of relapse in neuromyelitis optica spectrum disorder (NMOSD) mehr Published on: 9 September 2020 Roche expands its multiple sclerosis portfolio with investigational BTK inhibitor fenebrutinib and initiates novel clinical trials for OCREVUS (ocrelizumab) mehr Published on: 8 September 2020 Roche receives FDA clearance for BK virus quantitative test on cobas 6800/8800 Systems to support better care for transplant patients mehr Published on: 7 September 2020 Reminder: Invitation to Roche’s Virtual Pharma Day - Monday, 14th September 2020 mehr Published on: 7 September 2020 Roche announces FDA approval of Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer mehr Published on: 4 September 2020 Roche receives FDA Emergency Use Authorization for the cobas SARS-CoV-2 & Influenza A/B Test for use on the cobas 6800/8800 Systems mehr Published on: 3 September 2020 Roche to present new data in multiple sclerosis and neuromyelitis optica spectrum disorder at MSVirtual2020 mehr Published on: 1 September 2020 Roche to launch SARS-CoV-2 Rapid Antigen Test in countries accepting CE mark, allowing fast triage decisions at point of care mehr Published on: 1 September 2020 Roche receives FDA approval for first HIV-1/HIV-2 Qualitative Test on the cobas 6800/8800 Systems in the fight against HIV/AIDS mehr Published on: 28 August 2020 Roche announces FDA approval of FoundationOne Liquid CDx, a comprehensive pan-tumour liquid biopsy test mehr Published on: 19 August 2020 Reminder: Invitation to Roche’s Virtual Pharma Day - Monday, 14th September 2020 mehr Published on: 19 August 2020 Roche and Regeneron collaborate to significantly increase global supply of REGN-COV2 investigational antibody combination for COVID-19 mehr Published on: 17 August 2020 FDA Approves Roche’s ENSPRYNG for Neuromyelitis Optica Spectrum Disorder (NMOSD) mehr Published on: 13 August 2020 FDA accepts application for Xolair (omalizumab) prefilled syringe for self-administration across all indications mehr Published on: 10 August 2020 FDA approves Roche’s Evrysdi (risdiplam) for treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older mehr Published on: 10 August 2020 Roche provides update on phase III studies of etrolizumab in people with moderately to severely active ulcerative colitis mehr Published on: 6 August 2020 Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer mehr Published on: 5 August 2020 Roche announces FDA authorisation for the first Epstein-Barr virus quantitative test on the cobas 6800/8800 Systems to improve care for transplant patients mehr Published on: 3 August 2020 Rozlytrek, Roche’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer mehr Published on: 31 Juli 2020 FDA approves Roche’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma mehr Published on: 29 Juli 2020 FDA approves Roche’s new VENTANA HER2 Dual ISH test as companion diagnostic to identify breast cancer patients eligible for targeted therapy mehr Published on: 29 Juli 2020 Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia mehr Published on: 24 Juli 2020 Sarepta Therapeutics Receives Fast Track Designation for SRP-9001 Micro-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy mehr Published on: 24 Juli 2020 Invitation to Roche’s Virtual Pharma Day - Monday, 14th September 2020 mehr Published on: 23 Juli 2020 First half of the year with 1% growth at constant exchange rates, significant impact of COVID-19 pandemic mehr Published on: 22 Juli 2020 Phase III data show Roche’s Port Delivery System with ranibizumab enabled over 98% of patients to go six months between treatments for neovascular age-related macular degeneration mehr Published on: 16 Juli 2020 Reminder: Invitation to Roche’s virtual event on key ophthalmology data presented at the American Society of Retina Specialists 38th Annual Meeting mehr Published on: 16 Juli 2020 Reminder: Invitation to Roche’s Half Year Results 2020 Live Video Webcast and Conference Call mehr Published on: 15 Juli 2020 Reminder: New Format and E-Mail Address for Roche Investor Updates mehr Published on: 14 Juli 2020 FDA grants Breakthrough Therapy Designation for Roche’s CD20xCD3 bispecific cancer immunotherapy mosunetuzumab recognising its potential in follicular lymphoma mehr Published on: 14 Juli 2020 Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers mehr Published on: 13 Juli 2020 Spark Therapeutics Announces Updated Data on SPK-8011 from Phase 1/2 Clinical Trial in Hemophilia A at ISTH 2020 Virtual Congress mehr Published on: 13 Juli 2020 New data from phase IIIb study reinforces safety profile of Roche’s Hemlibra in people with haemophilia A mehr Published on: 13 Juli 2020 Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer mehr Published on: 6 Juli 2020 New Format and E-Mail Address for Roche Investor Updates mehr Published on: 1 Juli 2020 Invitation to Roche’s virtual event on key ophthalmology data presented at the American Society of Retina Specialists 38th Annual Meeting mehr Published on: 29 Juni 2020 FDA approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer mehr Published on: 29 Juni 2020 Roche announces new data at the ISTH 2020 Congress, demonstrating ongoing commitment to advancing care for people with haemophilia A mehr Published on: 29 Juni 2020 Roche’s ENSPRYNG®️ (satralizumab) approved in Japan for adults and children with neuromyelitis optica spectrum disorder mehr Published on: 26 Juni 2020 Roche improves speed and accuracy of non-small cell lung cancer diagnosis with launch of automated digital pathology algorithm mehr Published on: 25 Juni 2020 Invitation to Roche’s Half Year Results 2020 Live Video Webcast and Conference Call mehr Published on: 19 Juni 2020 Roche’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints mehr Published on: 18 Juni 2020 Roche’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer mehr Published on: 16 Juni 2020 Sarepta Therapeutics Announces Positive Safety and Efficacy Data from the SRP-9001 Micro-Dystrophin Gene Therapy Trial Published in JAMA Neurology mehr Published on: 15 Juni 2020 Foundation Medicine Acquires Lexent Bio, Inc., to Accelerate Liquid Biopsy Research and Development, and Advance Cancer Care mehr Published on: 13 Juni 2020 Positive phase III results for Venclexta/Venclyxto combination in acute myeloid leukaemia presented at EHA 2020 mehr Published on: 12 Juni 2020 Roche announces 2-year risdiplam data from SUNFISH and new data from JEWELFISH in infants, children and adults with spinal muscular atrophy (SMA) mehr Published on: 12 Juni 2020 Roche presents updated data on novel CD20xCD3 bispecific cancer immunotherapy glofitamab in people with heavily pre-treated non-Hodgkin lymphomas mehr Published on: 4 Juni 2020 Roche’s Elecsys IL-6 test receives FDA Emergency Use Authorization to help in identifying patients at high risk of severe inflammatory response mehr Published on: 2 Juni 2020 FDA approves Roche’s Tecentriq in combination with Avastin for people with the most common form of liver cancer mehr Published on: 29 Mai 2020 CHMP recommends EU approval of Roche’s Rozlytrek for people with NTRK fusion-positive solid tumours and for people with ROS1-positive, advanced non-small cell lung cancer mehr Published on: 29 Mai 2020 Updated data demonstrate Roche’s Alecensa increases overall survival rate for people with ALK-positive non-small cell lung cancer mehr Published on: 28 Mai 2020 Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time approved in Europe mehr Published on: 28 Mai 2020 Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia mehr Published on: 27 Mai 2020 Roche’s Port Delivery System with ranibizumab shows positive phase III results in neovascular age-related macular degeneration mehr Published on: 25 Mai 2020 Reminder: Invitation to Roche’s virtual event on key oncology data presented at ASCO 2020 mehr Published on: 22 Mai 2020 Roche acquires Stratos Genomics to further develop DNA based sequencing for diagnostic use mehr Published on: 22 Mai 2020 New longer-term data reinforce safety of Roche’s satralizumab in adults and adolescents with neuromyelitis optica spectrum disorder mehr Published on: 19 Mai 2020 FDA approves Roche’s Tecentriq as a first-line monotherapy for certain people with metastatic non-small cell lung cancer mehr Published on: 15 Mai 2020 Roche launches new blood gas digital solution designed to improve patient care mehr Published on: 14 Mai 2020 Roche to present first clinical data on novel anti-TIGIT cancer immunotherapy tiragolumab at ASCO mehr Published on: 11 Mai 2020 A formative figure in the company's history: Roche Honorary Chairman Fritz Gerber dies at the age of 91 mehr Published on: 11 Mai 2020 Wechsel in der erweiterten Konzernleitung von Roche mehr Published on: 7 Mai 2020 New data at the ASCO20 Virtual Scientific Program reflects Roche’s commitment to accelerating progress in cancer care mehr Published on: 6 Mai 2020 Invitation to Roche’s virtual event on key oncology data presented at ASCO 2020 mehr Published on: 3 Mai 2020 Roche’s COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark mehr Published on: 30 April 2020 Reminder: Invitation to Roche’s Virtual Event “Digital technology and advanced analytics in Roche” mehr Published on: 28 April 2020 New 6-year data for Roche’s OCREVUS (ocrelizumab) show earlier treatment initiation nearly halves risk of needing walking aid in relapsing multiple sclerosis mehr Published on: 28 April 2020 Roche’s risdiplam shows significant improvement in survival and motor milestones in infants with Type 1 spinal muscular atrophy (SMA) mehr Published on: 24 April 2020 Positive Results from the Phase III SAkuraStar Study for Satralizumab in NMOSD Published in The Lancet Neurology mehr Published on: 22 April 2020 First quarter with 2% growth in Swiss francs, 7% at constant exchange rates mehr Published on: 21 April 2020 Reminder: Invitation to Roche’s live audio webcast on new AAN 2020 data mehr Published on: 21 April 2020 Roche receives FDA approval for cobas HPV test for use on the cobas 6800/8800 Systems to identify women at risk for cervical cancer mehr Published on: 20 April 2020 US FDA and EMA accept applications for Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time mehr Published on: 17 April 2020 Roche develops new serology test to detect COVID-19 antibodies mehr Published on: 15 April 2020 Reminder: Invitation to Roche’s First Quarter Sales 2020 Audio Webcast and Conference Call mehr Published on: 8 April 2020 Chugai Starts Phase III Clinical Trial of Actemra for COVID-19 Pneumonia in Japan mehr Published on: 8 April 2020 Invitation to Roche’s live audio webcast on new AAN 2020 data mehr Published on: 7 April 2020 Roche provides regulatory update on risdiplam for the treatment of spinal muscular atrophy (SMA) mehr Published on: 7 April 2020 Invitation to Roche’s Virtual Event “Digital technology and advanced analytics in Roche” mehr Published on: 27 März 2020 FDA accepts Roche’s New Drug Application for Xofluza (baloxavir marboxil) for the treatment of influenza in children mehr Published on: 25 März 2020 Invitation to Roche’s First Quarter Sales 2020 Audio Webcast and Conference Call mehr Published on: 24 März 2020 Roche response to COVID-19 pandemic mehr Published on: 23 März 2020 Roche announces Venclexta/Venclyxto combination improved overall survival in people with previously untreated acute myeloid leukaemia mehr Published on: 19 März 2020 Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia mehr Published on: 17 März 2020 Roche Annual General Meeting 2020 mehr Published on: 16 März 2020 Roche Annual General Meeting 2020: Voting will take place by independent proxy. Participation on site is neither possible nor permitted by Federal Council ordinance mehr Published on: 14 März 2020 Roche Annual General Meeting 2020 to take place under special conditions set by the authorities - electronic voting strongly recommended mehr Published on: 13 März 2020 Roche’s cobas SARS-CoV-2 Test to detect novel coronavirus receives FDA Emergency Use Authorization and is available in markets accepting the CE mark mehr Published on: 12 März 2020 European Commission approves Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia mehr Published on: 11 März 2020 Roche receives FDA approval for CINtec PLUS Cytology test to aid clinicians in improving cervical cancer prevention mehr Published on: 4 März 2020 FDA grants Breakthrough Device Designation for Roche's Elecsys GALAD score to support earlier diagnosis of hepatocellular carcinoma mehr Published on: 3 März 2020 FDA grants Breakthrough Therapy Designation for Roche’s Esbriet (pirfenidone) in unclassifiable interstitial lung disease mehr Published on: 25 Februar 2020 FDA accepts Roche’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer mehr Published on: 21 Februar 2020 Chugai Obtains Approval for Additional Indication of Rozlytrek for ROS1 Fusion-Positive Non-Small Cell Lung Cancer mehr Published on: 19 Februar 2020 FDA grants priority review to Roche’s Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer mehr Published on: 14 Februar 2020 China National Medical Products Administration grants approval of Roche’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer mehr Published on: 11 Februar 2020 Reminder: Invitation to Roche’s Virtual Early Drug Development gRED Event 2020 mehr Published on: 10 Februar 2020 Roche provides topline results from investigator-led Phase II/III trial with gantenerumab in rare inherited form of Alzheimer’s disease mehr Published on: 7 Februar 2020 Roche to present new data on Tecentriq in combination with Avastin that shows improvement in overall survival for Chinese patients with the most common form of liver cancer mehr Published on: 6 Februar 2020 Roche’s risdiplam showed significant improvement in motor function in people aged 2-25 with type 2 or 3 spinal muscular atrophy mehr Published on: 31 Januar 2020 Roche announces CHMP recommendation for EU approval of Venclyxto plus Gazyvaro for people with untreated chronic lymphocytic leukaemia mehr Published on: 31 Januar 2020 Reminder: Invitation to Roche’s live audio webcast on efficacy and safety of risdiplam in patients with type 2/3 spinal muscular atrophy presented at SMA Europe 2020 mehr Published on: 30 Januar 2020 Roche reports very strong results in 2019 mehr Published on: 27 Januar 2020 Invitation to Roche’s Virtual Early Drug Development gRED Event 2020 mehr Published on: 27 Januar 2020 Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer mehr Published on: 24 Januar 2020 Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer mehr Published on: 23 Januar 2020 Reminder: Invitation to Roche’s Full Year Results 2019 Presentation mehr Published on: 23 Januar 2020 Roche’s Risdiplam meets primary endpoint in pivotal FIREFISH trial in infants with type 1 spinal muscular atrophy mehr Published on: 21 Januar 2020 European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma mehr Published on: 17 Januar 2020 Invitation to Roche’s live audio webcast on efficacy and safety of risdiplam in patients with type 2/3 spinal muscular atrophy presented at SMA Europe 2020 mehr Published on: 13 Januar 2020 Roche and Illumina partner to broaden patient access to genomic testing mehr Published on: 10 Januar 2020 Reminder: Invitation to Roche’s Full Year Results 2019 Presentation mehr Published on: 2 Januar 2020 F1CDx approved in Japan as a CDx of ROS1+NSCLC for Rozlytrek mehr
Published on: 22 Oktober 2020 Roche announces collaboration with Atea Pharmaceuticals to develop a potential oral treatment for COVID-19 patients mehr
Published on: 19 Oktober 2020 Roche announces full FDA approval for Venclexta combinations for acute myeloid leukaemia mehr
Published on: 15 Oktober 2020 Chugai Files NDA for Risdiplam as the First Oral Drug for Spinal Muscular Atrophy in Japan mehr
Published on: 15 Oktober 2020 First nine months of the year with 1% sales growth at constant exchange rates, significant impact of COVID-19 pandemic mehr
Published on: 13 Oktober 2020 Roche to launch laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients mehr
Published on: 30 September 2020 Regeneron's REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19 Patients mehr
Published on: 28 September 2020 Sarepta Therapeutics Reports Sustained Functional Improvement Two Years After Treatment with SRP-9001, its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy mehr
Published on: 28 September 2020 Roche presents new 2-year data for Evrysdi (risdiplam) in infants with Type 1 spinal muscular atrophy (SMA) mehr
Published on: 25 September 2020 Tecentriq in combination with Avastin in 1L HCC approved in Japan mehr
Published on: 19 September 2020 Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020 mehr
Published on: 18 September 2020 Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer mehr
Published on: 18 September 2020 Roche launches new quantitative antibody test to measure SARS-CoV-2 antibodies, to support the evaluation of vaccines mehr
Published on: 18 September 2020 Roche’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia mehr
Published on: 17 September 2020 Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020 mehr
Published on: 16 September 2020 Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer mehr
Published on: 11 September 2020 New data further reinforce Roche’s OCREVUS (ocrelizumab) as a highly effective treatment for people with multiple sclerosis mehr
Published on: 10 September 2020 New data show Roche’s ENSPRYNG (satralizumab) significantly reduces severity and risk of relapse in neuromyelitis optica spectrum disorder (NMOSD) mehr
Published on: 9 September 2020 Roche expands its multiple sclerosis portfolio with investigational BTK inhibitor fenebrutinib and initiates novel clinical trials for OCREVUS (ocrelizumab) mehr
Published on: 8 September 2020 Roche receives FDA clearance for BK virus quantitative test on cobas 6800/8800 Systems to support better care for transplant patients mehr
Published on: 7 September 2020 Reminder: Invitation to Roche’s Virtual Pharma Day - Monday, 14th September 2020 mehr
Published on: 7 September 2020 Roche announces FDA approval of Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer mehr
Published on: 4 September 2020 Roche receives FDA Emergency Use Authorization for the cobas SARS-CoV-2 & Influenza A/B Test for use on the cobas 6800/8800 Systems mehr
Published on: 3 September 2020 Roche to present new data in multiple sclerosis and neuromyelitis optica spectrum disorder at MSVirtual2020 mehr
Published on: 1 September 2020 Roche to launch SARS-CoV-2 Rapid Antigen Test in countries accepting CE mark, allowing fast triage decisions at point of care mehr
Published on: 1 September 2020 Roche receives FDA approval for first HIV-1/HIV-2 Qualitative Test on the cobas 6800/8800 Systems in the fight against HIV/AIDS mehr
Published on: 28 August 2020 Roche announces FDA approval of FoundationOne Liquid CDx, a comprehensive pan-tumour liquid biopsy test mehr
Published on: 19 August 2020 Reminder: Invitation to Roche’s Virtual Pharma Day - Monday, 14th September 2020 mehr
Published on: 19 August 2020 Roche and Regeneron collaborate to significantly increase global supply of REGN-COV2 investigational antibody combination for COVID-19 mehr
Published on: 17 August 2020 FDA Approves Roche’s ENSPRYNG for Neuromyelitis Optica Spectrum Disorder (NMOSD) mehr
Published on: 13 August 2020 FDA accepts application for Xolair (omalizumab) prefilled syringe for self-administration across all indications mehr
Published on: 10 August 2020 FDA approves Roche’s Evrysdi (risdiplam) for treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older mehr
Published on: 10 August 2020 Roche provides update on phase III studies of etrolizumab in people with moderately to severely active ulcerative colitis mehr
Published on: 6 August 2020 Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer mehr
Published on: 5 August 2020 Roche announces FDA authorisation for the first Epstein-Barr virus quantitative test on the cobas 6800/8800 Systems to improve care for transplant patients mehr
Published on: 3 August 2020 Rozlytrek, Roche’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer mehr
Published on: 31 Juli 2020 FDA approves Roche’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma mehr
Published on: 29 Juli 2020 FDA approves Roche’s new VENTANA HER2 Dual ISH test as companion diagnostic to identify breast cancer patients eligible for targeted therapy mehr
Published on: 29 Juli 2020 Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia mehr
Published on: 24 Juli 2020 Sarepta Therapeutics Receives Fast Track Designation for SRP-9001 Micro-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy mehr
Published on: 24 Juli 2020 Invitation to Roche’s Virtual Pharma Day - Monday, 14th September 2020 mehr
Published on: 23 Juli 2020 First half of the year with 1% growth at constant exchange rates, significant impact of COVID-19 pandemic mehr
Published on: 22 Juli 2020 Phase III data show Roche’s Port Delivery System with ranibizumab enabled over 98% of patients to go six months between treatments for neovascular age-related macular degeneration mehr
Published on: 16 Juli 2020 Reminder: Invitation to Roche’s virtual event on key ophthalmology data presented at the American Society of Retina Specialists 38th Annual Meeting mehr
Published on: 16 Juli 2020 Reminder: Invitation to Roche’s Half Year Results 2020 Live Video Webcast and Conference Call mehr
Published on: 14 Juli 2020 FDA grants Breakthrough Therapy Designation for Roche’s CD20xCD3 bispecific cancer immunotherapy mosunetuzumab recognising its potential in follicular lymphoma mehr
Published on: 14 Juli 2020 Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers mehr
Published on: 13 Juli 2020 Spark Therapeutics Announces Updated Data on SPK-8011 from Phase 1/2 Clinical Trial in Hemophilia A at ISTH 2020 Virtual Congress mehr
Published on: 13 Juli 2020 New data from phase IIIb study reinforces safety profile of Roche’s Hemlibra in people with haemophilia A mehr
Published on: 13 Juli 2020 Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer mehr
Published on: 1 Juli 2020 Invitation to Roche’s virtual event on key ophthalmology data presented at the American Society of Retina Specialists 38th Annual Meeting mehr
Published on: 29 Juni 2020 FDA approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer mehr
Published on: 29 Juni 2020 Roche announces new data at the ISTH 2020 Congress, demonstrating ongoing commitment to advancing care for people with haemophilia A mehr
Published on: 29 Juni 2020 Roche’s ENSPRYNG®️ (satralizumab) approved in Japan for adults and children with neuromyelitis optica spectrum disorder mehr
Published on: 26 Juni 2020 Roche improves speed and accuracy of non-small cell lung cancer diagnosis with launch of automated digital pathology algorithm mehr
Published on: 25 Juni 2020 Invitation to Roche’s Half Year Results 2020 Live Video Webcast and Conference Call mehr
Published on: 19 Juni 2020 Roche’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints mehr
Published on: 18 Juni 2020 Roche’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer mehr
Published on: 16 Juni 2020 Sarepta Therapeutics Announces Positive Safety and Efficacy Data from the SRP-9001 Micro-Dystrophin Gene Therapy Trial Published in JAMA Neurology mehr
Published on: 15 Juni 2020 Foundation Medicine Acquires Lexent Bio, Inc., to Accelerate Liquid Biopsy Research and Development, and Advance Cancer Care mehr
Published on: 13 Juni 2020 Positive phase III results for Venclexta/Venclyxto combination in acute myeloid leukaemia presented at EHA 2020 mehr
Published on: 12 Juni 2020 Roche announces 2-year risdiplam data from SUNFISH and new data from JEWELFISH in infants, children and adults with spinal muscular atrophy (SMA) mehr
Published on: 12 Juni 2020 Roche presents updated data on novel CD20xCD3 bispecific cancer immunotherapy glofitamab in people with heavily pre-treated non-Hodgkin lymphomas mehr
Published on: 4 Juni 2020 Roche’s Elecsys IL-6 test receives FDA Emergency Use Authorization to help in identifying patients at high risk of severe inflammatory response mehr
Published on: 2 Juni 2020 FDA approves Roche’s Tecentriq in combination with Avastin for people with the most common form of liver cancer mehr
Published on: 29 Mai 2020 CHMP recommends EU approval of Roche’s Rozlytrek for people with NTRK fusion-positive solid tumours and for people with ROS1-positive, advanced non-small cell lung cancer mehr
Published on: 29 Mai 2020 Updated data demonstrate Roche’s Alecensa increases overall survival rate for people with ALK-positive non-small cell lung cancer mehr
Published on: 28 Mai 2020 Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time approved in Europe mehr
Published on: 28 Mai 2020 Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia mehr
Published on: 27 Mai 2020 Roche’s Port Delivery System with ranibizumab shows positive phase III results in neovascular age-related macular degeneration mehr
Published on: 25 Mai 2020 Reminder: Invitation to Roche’s virtual event on key oncology data presented at ASCO 2020 mehr
Published on: 22 Mai 2020 Roche acquires Stratos Genomics to further develop DNA based sequencing for diagnostic use mehr
Published on: 22 Mai 2020 New longer-term data reinforce safety of Roche’s satralizumab in adults and adolescents with neuromyelitis optica spectrum disorder mehr
Published on: 19 Mai 2020 FDA approves Roche’s Tecentriq as a first-line monotherapy for certain people with metastatic non-small cell lung cancer mehr
Published on: 15 Mai 2020 Roche launches new blood gas digital solution designed to improve patient care mehr
Published on: 14 Mai 2020 Roche to present first clinical data on novel anti-TIGIT cancer immunotherapy tiragolumab at ASCO mehr
Published on: 11 Mai 2020 A formative figure in the company's history: Roche Honorary Chairman Fritz Gerber dies at the age of 91 mehr
Published on: 7 Mai 2020 New data at the ASCO20 Virtual Scientific Program reflects Roche’s commitment to accelerating progress in cancer care mehr
Published on: 6 Mai 2020 Invitation to Roche’s virtual event on key oncology data presented at ASCO 2020 mehr
Published on: 3 Mai 2020 Roche’s COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark mehr
Published on: 30 April 2020 Reminder: Invitation to Roche’s Virtual Event “Digital technology and advanced analytics in Roche” mehr
Published on: 28 April 2020 New 6-year data for Roche’s OCREVUS (ocrelizumab) show earlier treatment initiation nearly halves risk of needing walking aid in relapsing multiple sclerosis mehr
Published on: 28 April 2020 Roche’s risdiplam shows significant improvement in survival and motor milestones in infants with Type 1 spinal muscular atrophy (SMA) mehr
Published on: 24 April 2020 Positive Results from the Phase III SAkuraStar Study for Satralizumab in NMOSD Published in The Lancet Neurology mehr
Published on: 22 April 2020 First quarter with 2% growth in Swiss francs, 7% at constant exchange rates mehr
Published on: 21 April 2020 Reminder: Invitation to Roche’s live audio webcast on new AAN 2020 data mehr
Published on: 21 April 2020 Roche receives FDA approval for cobas HPV test for use on the cobas 6800/8800 Systems to identify women at risk for cervical cancer mehr
Published on: 20 April 2020 US FDA and EMA accept applications for Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time mehr
Published on: 15 April 2020 Reminder: Invitation to Roche’s First Quarter Sales 2020 Audio Webcast and Conference Call mehr
Published on: 8 April 2020 Chugai Starts Phase III Clinical Trial of Actemra for COVID-19 Pneumonia in Japan mehr
Published on: 7 April 2020 Roche provides regulatory update on risdiplam for the treatment of spinal muscular atrophy (SMA) mehr
Published on: 7 April 2020 Invitation to Roche’s Virtual Event “Digital technology and advanced analytics in Roche” mehr
Published on: 27 März 2020 FDA accepts Roche’s New Drug Application for Xofluza (baloxavir marboxil) for the treatment of influenza in children mehr
Published on: 25 März 2020 Invitation to Roche’s First Quarter Sales 2020 Audio Webcast and Conference Call mehr
Published on: 23 März 2020 Roche announces Venclexta/Venclyxto combination improved overall survival in people with previously untreated acute myeloid leukaemia mehr
Published on: 19 März 2020 Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia mehr
Published on: 16 März 2020 Roche Annual General Meeting 2020: Voting will take place by independent proxy. Participation on site is neither possible nor permitted by Federal Council ordinance mehr
Published on: 14 März 2020 Roche Annual General Meeting 2020 to take place under special conditions set by the authorities - electronic voting strongly recommended mehr
Published on: 13 März 2020 Roche’s cobas SARS-CoV-2 Test to detect novel coronavirus receives FDA Emergency Use Authorization and is available in markets accepting the CE mark mehr
Published on: 12 März 2020 European Commission approves Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia mehr
Published on: 11 März 2020 Roche receives FDA approval for CINtec PLUS Cytology test to aid clinicians in improving cervical cancer prevention mehr
Published on: 4 März 2020 FDA grants Breakthrough Device Designation for Roche's Elecsys GALAD score to support earlier diagnosis of hepatocellular carcinoma mehr
Published on: 3 März 2020 FDA grants Breakthrough Therapy Designation for Roche’s Esbriet (pirfenidone) in unclassifiable interstitial lung disease mehr
Published on: 25 Februar 2020 FDA accepts Roche’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer mehr
Published on: 21 Februar 2020 Chugai Obtains Approval for Additional Indication of Rozlytrek for ROS1 Fusion-Positive Non-Small Cell Lung Cancer mehr
Published on: 19 Februar 2020 FDA grants priority review to Roche’s Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer mehr
Published on: 14 Februar 2020 China National Medical Products Administration grants approval of Roche’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer mehr
Published on: 11 Februar 2020 Reminder: Invitation to Roche’s Virtual Early Drug Development gRED Event 2020 mehr
Published on: 10 Februar 2020 Roche provides topline results from investigator-led Phase II/III trial with gantenerumab in rare inherited form of Alzheimer’s disease mehr
Published on: 7 Februar 2020 Roche to present new data on Tecentriq in combination with Avastin that shows improvement in overall survival for Chinese patients with the most common form of liver cancer mehr
Published on: 6 Februar 2020 Roche’s risdiplam showed significant improvement in motor function in people aged 2-25 with type 2 or 3 spinal muscular atrophy mehr
Published on: 31 Januar 2020 Roche announces CHMP recommendation for EU approval of Venclyxto plus Gazyvaro for people with untreated chronic lymphocytic leukaemia mehr
Published on: 31 Januar 2020 Reminder: Invitation to Roche’s live audio webcast on efficacy and safety of risdiplam in patients with type 2/3 spinal muscular atrophy presented at SMA Europe 2020 mehr
Published on: 27 Januar 2020 Invitation to Roche’s Virtual Early Drug Development gRED Event 2020 mehr
Published on: 27 Januar 2020 Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer mehr
Published on: 24 Januar 2020 Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer mehr
Published on: 23 Januar 2020 Reminder: Invitation to Roche’s Full Year Results 2019 Presentation mehr
Published on: 23 Januar 2020 Roche’s Risdiplam meets primary endpoint in pivotal FIREFISH trial in infants with type 1 spinal muscular atrophy mehr
Published on: 21 Januar 2020 European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma mehr
Published on: 17 Januar 2020 Invitation to Roche’s live audio webcast on efficacy and safety of risdiplam in patients with type 2/3 spinal muscular atrophy presented at SMA Europe 2020 mehr
Published on: 13 Januar 2020 Roche and Illumina partner to broaden patient access to genomic testing mehr
Published on: 10 Januar 2020 Reminder: Invitation to Roche’s Full Year Results 2019 Presentation mehr